dorsaVi (ASX:DVL) is walking around with an impressive update on the commercialisation of its movement products

Matthijs Smith

Canaccord Genuity Australia

dorsaVi (ASX:DVL) is walking around with an impressive update on the commercialisation of its movement products. The company is rapidly growing its UK and US sales teams with 5 and 3 appointments in each market. In the OH&S space, one insurer is paying for DVL to do a workplace study at a client who has escalating OH&S claims. And the company has a whole bunch of new products coming on stream with a specific module to assess running going live this week and expected to be soft-launched at 15 Melbourne physio clinics over the next few months. The company expects physios will be able to charge $150-$250 for a running assessment which is not bad given most of the time the client is away running. I don't think it will be long before the medical market start to see DVL's products as a source of revenue rather than a cost.


MORE ON



Senior Life Sciences Analyst
Canaccord Genuity Australia

PhD Human Genetics, MBA, BSc Hons (1st Class). Sell side analyst specialising in life science companies since 2006. Previous background in biotech companies, medical research, consulting with BCG and scientific journalism with Nature

Expertise

No areas of expertise

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.